CompletedNCT07691190
Bioequivalence Study to Compare Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) Versus Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine)
Medication studyAges 18–55IndiaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- GujrātSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: March 5, 2026
- Recruitment status
- Completed
- Enrollment listed in the registry
- 32
- Sponsor
- Humanis Saglık Anonim Sirketi
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- India
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07691190
- Official title
Show the full official title
Single Dose Oral Bioequivalence Study of Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) and Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine) in Healthy Adult Human Participants Under Fasting Conditions.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Gujrāt
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Humanis Saglık Anonim Sirketi.
Did this study involve medication?
Yes. The study involved medication, including Cariprazine Hard Capsules and Reagila® Hartkapseln (Hard Capsules) (Cariprazine).
Who was this study for?
Listed age limits: 18 years to 55 years.
